A.A. MALOV¹, R.A. BASHIROV², S.Yu. AKHUNOVA³, A.F. YUSUPOVA¹

¹Kazan State Medical University of the MH of RF, 49 Butlerov Str., Kazan, Russian Federation, 420012

²Republican Clinical Hospital of the Ministry of Healthcare of the Republic of Tatarstan, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064

³Interregional Clinical Diagnostic Center, 12 Karbyshev Str., Kazan, Russian Federation, 420101

 Malov A.A. — Assistant of the Department of Oncology with a course in Radiology and Radiation Therapy, e-mail: malov_aleksei@inbox.ru, ORCID ID: 0000-0003-3261-9986

Bashirov R.A. — doctor-radiologist of the Department of Radiology, e-mail: rkbrad.mail.ru

Akhunova S.Yu. — PhD (medicine), Head of the Department of Functional Diagnostics, e-mail: svt400@mail.ru

Yusupova A.F. — PhD (medicine), Associate Professor of the Department of Oncology with a course in Radiology and Radiation Therapy, e-mail: a.f.yusupova@mail.ru

Hypertrophic cardiomyopathy is a heterogenic disease with varied clinical manifestations or an absence of such, with a broad age manifestation and the absence of gender regularities. One of the most complex forms is apical hypertrophic cardiomyopathy (AHCM). Its rare detectability is due to the difficulty of ultrasound visualization of the left ventricular apex, which leads to underestimation of its prevalence and the lack of reliable data on the stages and course of the disease. It is known that the apical form, as well as other forms of HCM, demonstrate proliferation of interstitial fibrosis, formation of apical aneurisms, development of potentially dangerous foci of ventricular ectopia, which poses a complicated clinical task to prevent sudden cardiac death. In the article, the complex of modern ultrasound and radiological diagnostic methods is viewed, as well as their possibilities for primary diagnostics and making a differential with the most frequent «masks» to assess the forecast of AHCM course.

Key words: apical hypertrophic cardiomyopathy (AHCM), single-photon emission computer tomography (SPECT), multiple detector computer tomography (MDCT), «Speckle-tracking» echocardiography, magnetic resonance tomography (MRI) of heart.

(For citation: Malov A.A., Bashirov R.A., Akhunova S.Yu., Yusupova A.F. Possibilities of cardiovascular imaging in diagnosing and assessment of progression of apical hypertrophic cardiomyopathy (AHCM) . Practical Medicine. 2018)

REFERENCES

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, pp. 2733-2779.
2. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.
3. Moon J.C.C., McKenna W.J., McCrohon J.A. et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. Am. Coll. Cardiol., 2003, 41, pp. 1561-7.
4. Jouni H., Geske J.B., Miller T.D. The diagnosis of apical hypertrophic cardiomyopathy with myocardial perfusion imaging. Heart, 2013, Jan 12.
5. Lang R.M., Bierig M., Devereux R.B. et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Am. Soc. Echocardiogr, 2005, 18, pp. 1440-63.
6. Caselli S., Pelliccia A., Maron M., et al. Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. J. Cardiol, 2008, 102, pp. 616-20.
7. Shirani J., Dilsizian V. Nuclear cardiac imaging in hypertrophic cardiomyopathy. Nucl. Cardiol, 2011, 18, pp. 123-34.
8. Schroeder S., Achenbach S., Bengel F. et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a writing group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Heart J, 2008, 29, pp. 531-56.
9. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Heart J. Cardiovascular Imaging, 2015, 16, p. 280.
10. Carsten Rickers, Norbert M. Wilke and oth. Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy. Circulation, 2005, 112, pp. 855-861.
11. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy. Am. Soc. Echocardiogr, 2011, 24, pp. 473-98.
12. Basavarajaiah S., Wilson M., Whyte G., et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to preparticipation screening. Am. Coll. Cardiol., 2008, 51, pp. 1033-9.
13. Bos J.M., Towbin J.A., Ackerman M.J. Diagnostic, prognostic, and therapeutic implication of genetic testing for hypertrophic cardiomyopathy. Am. Coll. Cardiol., 2009, 54, pp. 201-11.